Jinay Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 15-11-2024
- Paid Up Capital ₹ 0.10 M
as on 15-11-2024
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 160.87%
(FY 2023)
- Profit 240.14%
(FY 2023)
- Ebitda 299.04%
(FY 2023)
- Net Worth 364.75%
(FY 2023)
- Total Assets 83.46%
(FY 2023)
About Jinay Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Priyank Patani and Prakash Patani serve as directors at the Company.
- CIN/LLPIN
U74999MH2016PTC274449
- Company No.
274449
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Mar 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Jinay Pharmaceuticals Private Limited offer?
Jinay Pharmaceuticals Private Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Anti Infective Drugs & Medicines, Antifungal Injection, Tablet & Syrup, Cardiovascular Drugs & Medication, Blood Pressure Medicine, Common Disease Medicines, Pharmaceutical Capsules.
Who are the key members and board of directors at Jinay Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Priyank Patani  | Director | 15-Mar-2016 | Current |
| Prakash Patani | Director | 15-Mar-2016 | Current |
Financial Performance of Jinay Pharmaceuticals.
Jinay Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 160.87% increase. The company also saw a substantial improvement in profitability, with a 240.14% increase in profit. The company's net worth Soared by an impressive increase of 364.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jinay Pharmaceuticals?
In 2023, Jinay Pharmaceuticals had a promoter holding of 90.00% and a public holding of 10.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Jinay Pharmaceuticals?
Unlock and access historical data on people associated with Jinay Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jinay Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jinay Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
